姜儒鸿

2017-06-21


美国应用干细胞公司Applied StemCell,Inc (ASC)的共同创始人,董事长,总裁及首席执行官。美国应用干细胞公司以其独特的干细胞和精准基因修饰技术确立了其在干细胞、精准基因编辑和干细胞及基因治疗领域的国际领先地位。 自2008年成立以来,公司持续保持着年增长率100%以上的优秀业绩,几家国际著名生物创投机构投入2500万美元。 2014年4月和2016年9月两度被《自然生物技术》(Nature Biotechnology)评为“引领精准基因编辑应用技术的全球前十名公司”。

姜儒鸿博士1986年毕业于复旦大学生物系,1991年获北京农业大学硕士学位(现为中国农业大学),1997年在美国俄克拉荷马州立大学获博士学位。 毕业后进入德州贝勒医学院继续深造,在著名的Douglas Burrin博士组中作博士后。期间共发表学术论文40余篇,涵盖人类遗传学、药物基因组学及动物疾病模型等多个领域。姜儒鸿博士曾在多家美国生物技术和生物医药公司担任技术和管理要职。姜博士领导的课题组曾开发出全美市场最早的个性化药物诊断测试技术FamilionTM,该技术2007年市场利润超过1200万美元。 在创建美国应用干细胞公司之前,他曾任美国MicuRx医药有限公司中国区总经理,全权负责其在中国的业务。姜儒鸿博士对于个性化药物、再生医学和全球健康产业等课题有深入的研究。

姜儒鸿博士以其执着精进,敢为人先的创新精神,勤奋务实的工作作风,敏锐前瞻的市场洞察力,优秀的资源整合能力和真诚、谦虚、积极、乐观的处事风格,深受员工的爱戴和合作伙伴的尊敬,在业内具有良好的口碑和广泛的影响力。

Ruhong Jiang, Ph.D., is cofounder and CEO of Applied StemCell, Inc.  - A global leading company in stem cell and precise genome editing.  He has held a variety of technical and managerial roles with increasing responsibilities in several biotechnology/biopharmaceutical companies. Before starting Applied StemCell,Ruhong was general manager of MicuRx(Shanghai)Pharmaceutical,Inc. a California‐based biopharmaceutical company where he set up its entire China operation. From 2005‐2007, Dr. Jiang was head of the Pharmacogenetics Program at Stanford Research Institute International (SRI) where he managed multiple pharmacogenetic and molecular genetics projects with multi‐millions of annual budget. Prior to relocating to California, Dr. Jiang was pharmacogenomics consultant at Boehringer Ingelheim Pharmaceuticals and served as senior scientist, then director of project management at Genaissance Pharmaceuticals from 2000‐2004 where he played an important role in biomarker discovery, pharmacogenetics and clinical bioinformatics, diagnostic product development, alliance management and business development.  Dr. Jiang graduated from Fudan University with a B.S. degree in biology, and received M.S. degree in reproductive biology from China Agricultural University and a Ph.D. degree in Genetics from Oklahoma State University in 1997. From there Ruhong went to Baylor College of Medicine where he furthered his education as a postdoctoral fellow in Dr. Douglas Burrin’s lab. Dr. Jiang has authored and co‐authored more than 40 publications in the fields of human genetics, pharmacogenetics and disease animal models. Ruhong has a deep interest in the science, ethics and societal issues of personalized medicine, regenerative medicine and global health. His demonstrated leadership has led to an established track record of success; especially in the areas of biomarker‐based molecular assays or diagnosis, CRO service, and drug research and development.

上一篇:李凌衡
下一篇:王继武
Powered by 飞色网络